| abstract |
The invention provides a pharmaceutical product comprising, in combination, (1 ) (1 R,3aS,3bS,1 OaR, 10bS, 11 S,12aS)1-{[(cyanomethyl)sulfanyl]carbonyl}-7-(4-fluorophenyl)- 1 1 -hydroxy-10a,12a-dimethyl-1,2,3,3a,3b, 4,5,7,10,10a, 10b, 1 1,12,12a- tetradecahydrocyclopenta[1,2-f]indazol-1 -yl furan-2-carboxylat and (2) a 'beta'2 adrenoreceptor agonist, a dual 'beta'2 adrenoreceptor agonist/M3 receptor antagonist or a muscarinic antagonist, and the use of said product in treating respiratory diseases. |